Document is current

Article History

Received: 18 March 2024

Accepted: 10 February 2025

First Online: 3 March 2025

Declarations

:

: The study was approved by the lead Charité Ethics Committee, Berlin (EA4/169/19). Assent was given by the other responsible ethical review committees (Medical Association Hamburg, Medical Association Schleswig-Holstein, Hannover Medical School, Friedrich-Schiller University Jena, and the Medical Association Brandenburg). The study is registered at the German Clinical Trials Register (DRKS) under DRKS00019916. All potentially eligible participants will be approached to offer their informed consent to participate in the study. Additionally, they can accept to release their hospital administrative data in an optional consent form. For patients insured by participating sickness funds, a third consent form is handed out to ask for permission to process their insurance claims data at the end of the study period. Patients will be free to withdraw from either of the three consents without stating a reason. If the patients withdraw from the consent for participation, all their data will be deleted.

: Not Applicable.

: D. Schrednitzki reports payments for lectures and courses on knee arthroplasty and robotics from Zimmer Biomet, unrelated to this study. R. Busse reports institutional grants from Roche and Stryker, and speaker payments from AbbVie, all of which are unrelated to this study. R. Busse is also involved with the Government Commission on Hospital Reform. A. Halder reports royalties or licenses, speaker payments, and support for attending meetings and/or travel from Zimmer Biomet and DePuy, unrelated to this study. A. Halder is also President of the German Orthopaedic Society (DGOOC) 2022 Board Member European Knee Society. C. Pross is employed by Stryker, and reports stock in Stryker, unrelated to this study.